Program
poseltinib
Also written as “LY3337641”, “NB02 (Poseltinib)” and “LY3337641 (T1)”.
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 40 open or running | phase 2since Dec 9, 2015 | Dec 9, 2015 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since Jan 7, 2013 | Jan 7, 2013 | none ahead |
| NOBO Medicine | 11 open or running | phase 1since Jul 3, 2025 | Jul 3, 2025 | Dec 31, 2026phase 1 · NCT07114367 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2013First study: phase 1 study in Arthritis, RheumatoidNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01765478 · 62 enrolled · Netherlands
- Dec 9, 2015Eli Lilly's first study: phase 2 study in Arthritis, RheumatoidNew to Eli LillyEli Lilly · NCT02628028 · 286 enrolled · United States, Argentina, Australia and more
- Sep 21, 2016Phase 1 study in HealthyEli Lilly · NCT02914379 · 6 enrolled · United States
- Mar 14, 20172 phase 1 studies in HealthyEli Lilly · NCT03083561, NCT03099148
- Jul 3, 2025NOBO Medicine's first study: phase 1 study in Lymphoma, Non-HodgkinNew to NOBO MedicineNOBO Medicine · NCT07114367 · 9 planned · South Korea
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Lymphoma, Non-HodgkinNOBO Medicine · NCT07114367
TargetBeta
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07114367Lymphoma, Non-Hodgkin · South Korea | 1 | Recruiting | NOBO Medicine | Dec 31, 2026 | 9 |
| NCT03099148Healthy · Singapore | 1 | Completed | Eli Lilly | May 31, 2017 | 29 |
| NCT03083561Healthy · United States | 1 | Completed | Eli Lilly | May 25, 2017 | 36 |
| NCT02914379Healthy · United States | 1 | Completed | Eli Lilly | Nov 2016 | 6 |
| NCT02628028Arthritis, Rheumatoid · United States, Argentina, Australia and more | 2 | Terminated | Eli Lilly | Apr 25, 2018 | 286 |
| NCT01765478Arthritis, Rheumatoid · Netherlands | 1 | Completed | Hanmi Pharmaceutical | Nov 2014 | 62 |
How it is read
Names in the registry
- “LY3337641”, 2 entries
- “NB02 (Poseltinib)”, 1 entry
- “LY3337641 (T1)”, 1 entry
- “LY3337641 (T2)”, 1 entry
- “[¹⁴C]-LY3337641”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 2 studies
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.